To check Oneindia News on your Mobile
go to:   http://m.oneindia.in/news/
  •  

CP chooses Infy for Modular Global Sourcing

Bangalore, Aug 3: Infosys Technologies Limited, a world leader in consulting and information technology services, today announced a multi-year agreement with Canadian Pacific (CP) to provide Modular Global Sourcing services for its information technology organization, Business and Information Technology Services (BITS).

Infosys would help CP improve its IT delivery capabilities through BITS' strategic 'Bestshoring' initiative, Infosys said in a release here.

Canadian Pacific, headquartered in Calgary, Alberta, and its subsidiaries operated a 13,500-mile transcontinental railway that spans Canada and the Northeast and Midwest regions of the United States. CP also provided logistics, supply chain expertise and rail and intermodal transportation services.

''After evaluating several options, we selected Infosys because of its flexible, scalable solutions and expertise in delivering IT services globally best fit our current and future IT needs,'' said Kathryn McQuade, Executive VP and COO, Canadian Pacific in the release.

The five-year agreement would focus largely on the application development, management and maintenance of CP's railway operations.

BITS will be utilizing Infosys' CMM Level 5 capabilities, which would deliver the differentiated IT sourcing solutions that meet the specific accuracy requirements for CP's control hub's mission critical applications and train control operations.

''By closely examining CP's IT application landscape, Infosys was able to make key recommendations about how to implement its Bestshoring strategy,'' said Mr Paddy Rao, Head of Canada Integrated Business Unit at Infosys.

UNI

Biotechnology major Biocon forays into nephrology space

Bangalore, Mar 09:  Biotechnology major Biocon on Thursday forayed into the nephrology space with the launch of a portfolio of five renal therapy products for the domestic and global markets, which it said was cheaper compared to MNC drug prices. The new immunosuppressants for renal therapy are at least 35-40 per cent cheaper than the MNC drug prices in the similar product category, the company's Marketing Head Rakesh Bamzai said.The Bangalore-headquartered company's Chairman and Managing Director, Kiran Mazumdar-Shaw said.....
User Comments
[ Post Comments ]
Be the first to comment on this article.
Oneindia  Oneindia Login